Deciphera Pharmaceuticals’ $172 Million Follow-On Offering

Davis Polk advised the joint book-running managers in connection with the $172 million public offering of common stock of Deciphera Pharmaceuticals, Inc. The common stock is listed on the NASDAQ Global Select Market under the symbol “DCPH.”

JP Morgan, Piper Jaffray, Canaccord Genuity, JMP Securities, Nomura, Raymond James, J.P. Morgan and Piper Jaffray acted as joint book-running managers on the offering.

Headquartered in Waltham, Massachusetts, Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance that limit the rate and/or durability of response to existing cancer therapies. The company’s pipeline consists of tumor-targeted and immune-targeted drug candidates designed to improve outcomes for patients with cancer by improving the quality, rate and/or durability of their responses to treatment.

The Davis Polk corporate team included partner Richard D. Truesdell Jr. (Picture), counsel Jeffrey S. Ramsay and associates Jaryn S. Fields and Leigh Katz. Counsel David R. Bauer and associates Bonnie Chen and Jay Frankel provided intellectual property and technology advice. Partner Michael Mollerus and associate Liang Zhang provided tax advice. Counsel David A. Zilberberg provided environmental advice.

Involved fees earner: Richard Truesdell Jr. – Davis Polk & Wardwell; Jeffrey Ramsay – Davis Polk & Wardwell; Jaryn Fields – Davis Polk & Wardwell; Leigh Katz – Davis Polk & Wardwell; David Bauer – Davis Polk & Wardwell; Bonnie Chen – Davis Polk & Wardwell; Jay Frankel – Davis Polk & Wardwell; Michael Mollerus – Davis Polk & Wardwell; Liang Zhang – Davis Polk & Wardwell; David Zilberberg – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: JP Morgan; Canaccord Genuity; Nomura; Piper Jaffray & Co; JMP Securities LLC; Raymond James Financial, Inc.;


Author: Ambrogio Visconti